Impact of Artificial Intelligence on Prognosis, Shared Decision-making, and Precision Medicine for Patients with Inflammatory Bowel Disease: a Perspective and Expert Opinion

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Jan 1

PMID 38163336

Authors

Philippe Pinton

Affiliations

Soon will be listed here.

Abstract

Introduction: Artificial intelligence (AI) is expected to impact all facets of inflammatory bowel disease (IBD) management, including disease assessment, treatment decisions, discovery and development of new biomarkers and therapeutics, as well as clinician-patient communication.

Areas Covered: This perspective paper provides an overview of the application of AI in the clinical management of IBD through a review of the currently available AI models that could be potential tools for prognosis, shared decision-making, and precision medicine. This overview covers models that measure treatment response based on statistical or machine-learning methods, or a combination of the two. We briefly discuss a computational model that allows integration of immune/biological system knowledge with mathematical modeling and also involves a 'digital twin', which allows measurement of temporal trends in mucosal inflammatory activity for predicting treatment response. A viewpoint on AI-enabled wearables and nearables and their use to improve IBD management is also included.

Expert Opinion: Although challenges regarding data quality, privacy, and security; ethical concerns; technical limitations; and regulatory barriers remain to be fully addressed, a growing body of evidence suggests a tremendous potential for integration of AI into daily clinical practice to enable precision medicine and shared decision-making.

Citing Articles

Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores.

Shim J, Rehberg M, Wagenhuber B, van der Graaf P, Chung D Front Pharmacol. 2025; 16:1479666.

PMID: 40070575 PMC: 11893853. DOI: 10.3389/fphar.2025.1479666.

The Heart of Transformation: Exploring Artificial Intelligence in Cardiovascular Disease.

Chowdhury M, Rizk R, Chiu C, Zhang J, Scholl J, Bosch T Biomedicines. 2025; 13(2).

PMID: 40002840 PMC: 11852486. DOI: 10.3390/biomedicines13020427.

Exploring intimacy and family planning in Inflammatory Bowel Diseases: a qualitative study.

Gabova K, Bednarikova H, Meier Z, Tavel P Ann Med. 2024; 56(1):2401610.

PMID: 39552336 PMC: 11574974. DOI: 10.1080/07853890.2024.2401610.

Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease.

Yeshi K, Jamtsho T, Wangchuk P Molecules. 2024; 29(16).

PMID: 39203033 PMC: 11357616. DOI: 10.3390/molecules29163954.

Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.

Mestrovic A, Perkovic N, Bozic D, Kumric M, Vilovic M, Bozic J Biomedicines. 2024; 12(7).

PMID: 39062093 PMC: 11274502. DOI: 10.3390/biomedicines12071520.

References

Alric H, Amiot A, Kirchgesner J, Treton X, Allez M, Bouhnik Y . Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease. Inflamm Bowel Dis. 2021; 28(2):218-225. DOI: 10.1093/ibd/izab060. View

Davenport T, Kalakota R . The potential for artificial intelligence in healthcare. Future Healthc J. 2019; 6(2):94-98. PMC: 6616181. DOI: 10.7861/futurehosp.6-2-94. View

Pinton P . Computational models in inflammatory bowel disease. Clin Transl Sci. 2022; 15(4):824-830. PMC: 9010263. DOI: 10.1111/cts.13228. View

Katkar G, Sayed I, Anandachar M, Castillo V, Vidales E, Toobian D . Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol. 2022; 5(1):231. PMC: 8921270. DOI: 10.1038/s42003-022-03168-4. View

Wang Y, Miller M, Astrakhan Y, Petersen B, Schreiber S, Franke A . Identifying Crohn's disease signal from variome analysis. Genome Med. 2019; 11(1):59. PMC: 6767648. DOI: 10.1186/s13073-019-0670-6. View

Tontini G, Vecchi M, Pastorelli L, Neurath M, Neumann H . Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015; 21(1):21-46. PMC: 4284336. DOI: 10.3748/wjg.v21.i1.21. View

Bruining D, Zimmermann E, Loftus Jr E, Sandborn W, Sauer C, Strong S . Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018; 154(4):1172-1194. DOI: 10.1053/j.gastro.2017.11.274. View

Dercle L, Fronheiser M, Lu L, Du S, Hayes W, Leung D . Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. Clin Cancer Res. 2020; 26(9):2151-2162. PMC: 9239371. DOI: 10.1158/1078-0432.CCR-19-2942. View

Dong Y, Xu L, Fan Y, Xiang P, Gao X, Chen Y . A novel surgical predictive model for Chinese Crohn's disease patients. Medicine (Baltimore). 2019; 98(46):e17510. PMC: 6867775. DOI: 10.1097/MD.0000000000017510. View

10.

Mosli M, Feagan B, Sandborn W, DHaens G, Behling C, Kaplan K . Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014; 20(3):564-75. DOI: 10.1097/01.MIB.0000437986.00190.71. View

11.

Brooks-Warburton J, Ashton J, Dhar A, Tham T, Allen P, Hoque S . Artificial intelligence and inflammatory bowel disease: practicalities and future prospects. Frontline Gastroenterol. 2022; 13(4):325-331. PMC: 9186028. DOI: 10.1136/flgastro-2021-102003. View

12.

Siegel C, Horton H, Siegel L, K D Thompson , Mackenzie T, Stewart S . A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther. 2015; 43(2):262-71. DOI: 10.1111/apt.13460. View

13.

Jimenez-Luna J, Grisoni F, Weskamp N, Schneider G . Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov. 2021; 16(9):949-959. DOI: 10.1080/17460441.2021.1909567. View

14.

Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H . Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. Gastroenterology. 2020; 158(8):2150-2157. DOI: 10.1053/j.gastro.2020.02.012. View

15.

Venkatapurapu S, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R . A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther. 2022; 39(7):3225-3247. PMC: 9239932. DOI: 10.1007/s12325-022-02144-y. View

16.

Stidham R, Takenaka K . Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice?. Gastroenterology. 2022; 162(5):1493-1506. PMC: 8997186. DOI: 10.1053/j.gastro.2021.12.238. View

17.

Dulai P, Wan Y, Huang Z, Luo M . Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease. Crohns Colitis 360. 2023; 4(4):otac048. PMC: 9802432. DOI: 10.1093/crocol/otac048. View

18.

Park S, Kim Y, Kim S, Lee C, Choi C, Kang S . Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn's Disease Using Transcriptome Imputed from Genotypes. J Pers Med. 2022; 12(6). PMC: 9224874. DOI: 10.3390/jpm12060947. View

19.

Ashton J, Mossotto E, Ennis S, Beattie R . Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019; 8(1):56-69. PMC: 6382508. DOI: 10.21037/tp.2018.12.03. View

20.

Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade R . Artificial intelligence in drug discovery and development. Drug Discov Today. 2020; 26(1):80-93. PMC: 7577280. DOI: 10.1016/j.drudis.2020.10.010. View